Drugs / mNEXSPIKE
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | mNexspike | — | 2026-02-12 | europa.eu ↗ |
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07051031 | Oct 2025 → Jun 2026 overdue | COVID-19 | Marcel Curlin | Active not recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-04-18 | Sanofi | Press Release: ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study sanofi.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mNEXSPIKE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07051031 ↗ |
| Known as | mRNA-1283 | “mNEXSPIKE mRNA-1283” NCT07051031 ↗ |
| Modality | Messenger RNA (mRNA) | “mRNA-based vaccine” NCT07051031 ↗ |